Actinium Pharmaceuticals Aktie
WKN DE: A110R5 / ISIN: US00507W1071
|
23.10.2026 16:46:22
|
Actinium Advances HER3-Targeted Radiotherapy In Phase 1 Prostate Cancer Study
(RTTNews) - Actinium Pharmaceuticals (ATNM) announced that its first-in-human Phase 1 study of ATNM-400, an investigational HER3-targeted radiotherapy, will be featured at the ESMO 2026 Congress in Madrid, Spain, from October 23-27.
The study evaluates ATNM-400 in patients with metastatic castration-resistant prostate cancer (mCRPC), including those with and without prior PSMA-directed therapy. The therapy combines a HER3-targeting antibody with the alpha-emitting isotope Actinium-225, offering an approach distinct from PSMA-targeted treatments.
The multicenter, open-label study assesses safety, tolerability, dosimetry, pharmacokinetics and antitumor activity to determine a recommended Phase 2 dose. Patients undergo Zirconium-89-labeled imaging to assess tumor uptake before therapeutic treatment. The ESMO presentation is listed as an ePoster under "Trial in Progress."
Currently, ATNM is trading at $1.54, down 3.78%.
Der finanzen.at Ratgeber für Aktien!
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Actinium Pharmaceuticals Inc
| Keine Nachrichten verfügbar. |